ticlopidine, Ticlid (discontinued brand in the US)

Omudhome Ogbru, PharmD

Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

Jay W. Marks, MD

Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

GENERIC NAME: ticlopidine

BRAND NAME: Ticlid (Discontinued brand in the US)

DRUG CLASS AND MECHANISM: Ticlopidine is an oral drug that inhibits
the ability of platelets to clump and form blood clots. It prevents blood clots
by binding to the P2Y12 receptor on platelets, preventing adenosine diphosphate
(ADP) from activating platelets. It belongs to a class of drugs called P2Y12
inhibitors. Other drugs in this class include
clopidogrel (Plavix), ticagrelor (Brilinta)
and prasugrel (Effient). Clopidogrel is similar to ticlopidine (Ticlid) in
chemical structure and in the way it works. Blood clots that form within the
arteries of the brain or pieces of blood clots that break off from clots in
other parts of the body and lodge in blood vessels in the brain cause strokes.
Similarly, heart attacks occur when blood clots block an artery in the heart. In
both cases the blood supply to part of the brain or heart is blocked, and that
part of the brain or heart is damaged or dies. Ticlopidine works by making the
blood less likely to clot, therefore, reducing the likelihood of a stroke or
heart attack. The FDA approved ticlopidine in October 1991.